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Introduction
The gastrointestinal epithelium functions as a dynamic and selec-
tive barrier, which plays an important role in limiting the access 
of luminal contents to the mucosal and systemic immune system. 
Epithelial injury results in compromised barrier function, as seen 
in pathologic states that are associated with mucosal inflamma-
tion. A major consequence of the breeched epithelial barrier is 
exposure of immunocompetent subepithelial lamina propria cells 
to luminal antigens and bacteria. This results in local recruit-
ment of leukocytes and generation of proresolving mediators that 
orchestrate resolution of inflammation and ultimately epithelial 
repair. Thus, healing of epithelial wounds represents active coor-
dination of proresolving mediators and repair events, wherein 
platelets, fibroblasts, and epithelial, endothelial, and inflamma-
tory cells act together to restore the epithelial barrier and rees-
tablish mucosal homeostasis (1). Recent studies have highlighted 
a critical role of secreted lipids and proteins in facilitating epithe-
lial wound repair. Such proresolving mediators include lipoxins, 
resolvins, protectins, maresins, prostaglandins, cytokines, and 
annexin A1 (ANXA1) (2, 3).
ANXA1 facilitates resolution of inflammation by binding to 
formyl peptide receptors (FPRs) expressed on responsive cells, 
such as phagocytes and epithelial cells (4–6). We have previously 
shown that ANXA1 stimulates intestinal mucosal wound repair in 
a murine model of colitis (7). However, the mechanism by which 
this cytosolic protein activates prorestitutive signaling after injury 
is not understood. Furthermore, the mechanics of how ANXA1 
itself is regulated remain to be defined.
Neutrophils express ANXA1, and recent studies have demon-
strated that ANXA1 is released from them as a component of 
extracellular vesicles (EVs) (8, 9). EVs are subclassified into exo-
somes and microparticles (10). Exosomes are 40 to 60 nm in 
size and are produced by dendritic cells, macrophages, epithelial 
cells, and a variety of tumor cells. They are formed by membrane 
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In this work, we demonstrate that epithelial cells release the 
potent endogenous proresolving mediator ANXA1 as a compo-
nent of EVs that promote intestinal mucosal wound repair. Fur-
thermore, we investigate the therapeutic wound-healing proper-
ties of an ANXA1 mimetic peptide Ac2-26 that is delivered using 
polymeric nanoparticles (NPs). Since NPs can be synthesized with 
unique bioavailability and degradation properties, we harnessed 
the novel prorepair properties of the ANXA1 mimetic peptide Ac2-
26 by administering NPs encapsulating this peptide (Ac2-26 Col 
IV NPs) (15). Remarkably, a single systemic administration of the 
Ac2-26 Col IV NPs was sufficient in accelerating epithelial barrier 
repair during the resolution phase of murine colitis. Similarly, a 
invaginations and are released when intracellular vesicles com-
bine with a multivesicular body, which then fuses with the plasma 
membrane and results in exocytosis (10). Membrane-bound pro-
teins most commonly associated with exosomes include tetra-
spanins, specifically CD9 and CD63, which have been used in 
previous studies as markers of intestinal epithelial-derived exo-
somes (11, 12). In contrast to exosomes, microparticles are larger 
(100 to 1,000 nm) and are released by plasma membrane shed-
ding via a processes also referred to as ectocytosis (13). EVs can 
either disperse in the extracellular space near the site of release 
or over significant distances, ultimately appearing in biological 
fluids, such as plasma, serum, and urine (14). 
Figure 1. Intestinal epithelial wounding induces release of ANXA1-bearing EVs. (A) Immunoblotting for ANXA1 protein in supernatant of nonwounded 
(nw) or wounded (wound) human epithelial cells. Densitometry analysis shows that ANXA1 protein in cell supernatants derived from wounded cells is 
significantly increased versus nonwounded confluent cells (2.94-fold increase, P < 0.0001, average of n = 5 immunoblots), and no significant change was 
observed in the lysate. (B) Immunoblotting for ANXA1 protein in EVs isolated from supernatant. Densitometry analysis shows that ANXA1 protein on EVs 
derived from wounded cells is increased versus nonwounded cells (2.166-fold increase, P = 0.0066, average of n = 4 immunoblots). (C) Immunogold labeling 
for ANXA1 and transmission electron microscopy to detect ANXA1 distribution in EVs. Scale bar: 100 nm. (D) Immunoblotting for conventional EV markers 
in epithelial cell lysates (representative of n = 4 immunoblots). sADAM-10, soluble ADAM-10. (E) EVs were incubated with CD63+ Dynabeads and analyzed 
by immunoblotting. Densitometry analysis shows that ANXA1 protein on EVs derived from wounded cells is increased versus nonwounded cells (1.459-fold 
increase, P = 0.0004, average of n = 4 immunoblots). (F) Biotinylated cell surface proteins released from the supernatant of nonwounded and wounded 
IECs captured with avidin sepharose beads. Densitometry analysis shows that ANXA1 protein on EVs derived from wounded cells is increased versus non-
wounded cells (4.239-fold increase increase, P = 0.0002, average of n = 4 immunoblots). (G) Immunoblots show ANXA1 and CD9 proteins in EVs after IEC 
wounding and treatment with BAPTA-AM (30 μM), Z-VAD-FMK (25 mM), cytochalasin D (2 μM), jasplakinolide (1 μM), dynasore (80 μM), ML-7 (20 μM), and 
Y-27632 (10 μM). All the results in this figure are representative of at least 3 independent experiments.
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anism by which ANXA1 asso-
ciated with the inner leaflet of 
the plasma membrane gains 
access to extracellular sur-
face FPRs, we first determined 
whether ANXA1 was released 
from epithelial cells into the 
extracellular space. Indeed, 
as shown in Figure 1A, full-
length ANXA1 protein was 
identified in the supernatants 
of intestinal epithelial cells 
(IECs), and increased amounts 
of ANXA1 were released from 
the wounded epithelial cell 
monolayer (Figure 1A). We next 
sought to identify the protease 
that mediates ANXA1 cleav-
age in the extracellular com-
partment. Since MMPs target 
extracellular substrates, we 
examined whether epithelial- 
derived ANXA1 is cleaved by 
MMPs after IEC wounding 
(16). Incubation of epithe-
lial cells with MMP inhibi-
tors (TAPI-2, MMP9-selective 
inhibitor, and ADAM-10 inhib-
itor GI254023X) decreased the 
release of ANXA1 into the cell 
culture supernatant (Supple-
mental Figure 1A; supplemen-
tal material available online 
with this article; doi:10.1172/
JCI76693DS1). The MMP9-spe-
cific inhibitor displayed a sig-
nificant effect in decreasing 
ANXA1 release in EVs (Supple-
mental Figure 1B). To deter-
mine whether ANXA1 was 
released from human IECs as 
a component of EVs, particles 
were isolated by ultracentrifu-
gation from epithelial cell cul-
ture supernatants derived from 
either confluent IEC monolay-
ers or resealing wounds in vitro. As shown in the immunoblot 
in Figure 1B, ANXA1 was not only identified in EVs, but their 
release was increased during wound closure. ANXA5 and CD9 
have previously been shown to reside in EVs (10, 12); therefore, 
they were used as EVs markers. To further characterize ANXA1-
containing EVs, we performed immunogold labeling and elec-
tron microscopy of EVs isolated from supernatants of resealing 
IEC wounds. As shown in Figure 1C, ANXA1, ANXA5, and CD9 
were identified in round and cup-shaped vesicles characteristic 
of exosomes and in larger vesicles consistent with microparti-
cles. The presence of ANXA1 and the composition of EVs were 
single intramucosal injection of Ac2-26 Col IV NPs promoted clo-
sure of intestinal mucosal biopsy-induced wounds. These results 
indicate that NPs containing prorepair molecules are capable of 
not only improving resolution of inflammation but also function 
in accelerating ultimate recovery of the critical epithelial barrier 
function. Such delivery mechanisms can be used as novel thera-
peutic approaches to promote mucosal wound repair.
Results
ANXA1 released in intestinal epithelial-derived EVs plays an 
important role in promoting wound repair. To identify the mech-
Figure 2. EVs containing ANXA1 regulate epithelial wound healing. (A) Representative (of n = 5) en face image 
of migrating IECs after 24 hours of interaction with labeled EVs (CFSE, 10 μmol/l; Molecular Probes). The boxed 
area (original magnification, ×40) is shown at high magnification in the image below (original magnification, 
×100). Scale bar: 10 μm. (B and C) Scratch wound healing assay using IEC monolayers. EVs and hrANXA1 were 
added to wounded IECs alone and in the presence of FPR1 antagonist, CsH (1 μM); FPR2/ALX antagonist, WRW4 
(10 μM); and other conditions, as indicated. Wound widths were determined at time 0 and 24 hours (n = 5, mean 
± SEM) (original magnification, ×10). (D) Scratch wound healing assay using IEC monolayers. EVs were added to 
wounded IECs alone and in the presence of mouse monoclonal ANXA1 inhibitory antibody (250 μg/ml) or control 
IgG antibody (250 μg/ml). The experiments in C and D were repeated 3 times, and results of one representative 
experiment performed with 5 parallel samples are shown (mean ± SEM). ***P < 0.0001 compared with control; 
###P < 0.0001 compared with EVs. (E and F) IECs were incubated with EVs for 15 minutes, and ROS generation 
was detected by confocal microscopy using the fluorescent Hydro-Cy3 dye (15 μM). Scale bar: 40 μm. Summarized 
data for Hydro-Cy3 fluorescence intensity are presented in the graph (mean ± SEM, *P = 0.0002 vs. control, n = 3). 
Confocal micrographs are representative of 3 independent experiments. All the results in this figure are represen-
tative of at least 3 independent experiments. Statistical comparisons were performed by ANOVA with Tukey’s 
multiple comparison post-test for C and D and 2-tailed Student’s t test for F. RFU, relative fluorescent units. 
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is a calcium-dependent phospholipid- 
binding protein, and changes in intra-
cellular calcium concentrations have 
also been shown to influence genera-
tion of EVs (19, 20). Accordingly, we 
observed that chelation of intracellu-
lar calcium with BAPTA-AM reduced 
EV-associated ANXA1 (Figure 1G). 
Perturbation of F-actin dynamics with 
jasplakinolide or cytochalasin D (21) 
increased ANXA1 expression release in 
EVs (Figure 1G). Additionally, to study 
the role of actin myosin contraction, 
we analyzed Rho-associated kinase 
(ROCK) and myosin light chain kinase 
phosphorylation. ROCK inhibition with 
a small-molecule inhibitor, Y27632, 
but not with an inhibitor of myosin 
light chain kinase, ML-7, decreased 
ANXA1 release in EVs (Figure 1G). 
Consistently, the dynamin inhibitor, 
dynasore, decreased ANXA1 associ-
ation with EVs during wound closure. 
To exclude the possibility that ANXA1 
in IEC supernatants was derived from 
apoptotic cells, we inhibited apoptosis 
using a pan-caspase inhibitor (Z-VAD-
FMK). Then, we analyzed the amount 
of ANXA1 by immunoblotting EVs 
from resealing wounds (Figure 1G) and 
detected no differences.
To further characterize the EVs 
obtained from the culture superna-
tants of IEC lines during the wound 
closure model, we analyzed EVs by 
imaging flow cytometry as described 
recently (22). A detailed analysis of EVs 
with calibration beads ranging from 
1 μm to 50 nm was performed, and EVs 
were quantified in the supernatants of 
epithelial cells (Supplemental Figure 1, 
B–D). Our data revealed that inhibition 
of ROCK activity (with Y27632 compound) decreased ANXA1-
containing EVs, supporting a role of ROCK-mediated actin-myosin 
contraction in controlling the release of EVs loaded with ANXA1 
from epithelial cells (Figure 1G and Supplemental Figure 1C).
To determine whether the release of ANXA1-containing EVs 
from epithelial cells was altered in inflammatory states, we incu-
bated epithelial cells with proinflammatory cytokines (IL-1β, 
IFN-γ, and TNF-α). Analysis of cell culture supernatants upon sep-
aration by ultracentrifugation indicated that cytokines increased 
ANXA1 release in the EVs (Supplemental Figure 1D).
Taken together, these results show that ANXA1 release in 
IEC-derived EVs requires actin-myosin contraction and can be 
modulated by proinflammatory cytokines.
FPR signaling by ANXA1 in EVs promotes IEC wound closure. To 
assess the functional effects of ANXA1-containing EVs on epithe-
further evaluated by immunoblotting. In addition to ANXA1, 
ANXA5, CD9, EVs contained other previously reported EV- 
associated proteins, including flotillin, CD151, MMP2, MMP9, 
and ADAM-10 (refs. 10, 17, and Figure 1D).
Since the tetraspanin protein CD63 has been reported as a 
component of exosomes (18), we used ultracentrifugation and 
bead affinity purification to isolate CD63+ exosomes and subse-
quently detected ANXA1 by immunoblotting. As shown in Fig-
ure 1E, ANXA1 was identified in CD63-containing EVs, and this 
association was increased in supernatants from resealing IEC 
wounds. Furthermore, cell surface biotinylation experiments were 
performed to demonstrate that some of the ANXA1 in EVs was 
derived from the plasma membrane (Figure 1F).
Having shown that ANXA1 is released as a component of EVs, 
we investigated the mechanisms that control this process. ANXA1 
Figure 3. Analysis of ANXA1-containing EVs in ex vivo cultures of resealing mucosal wounds and func-
tional effects of EVs on wound closure. (A) 4-mm punch biopsy of resealing colonic wounds (1 day after 
injury, red circle) and nonwounded mucosa (blue circle) were rinsed in sterile PBS to remove cellular debris 
and immediately placed into a 24-well culture plate (3 wounds from each mouse per well, n = 4). Photo-
graphic images of a wound (1- to 2-mm size) and confocal images of resealing mucosal wound showing 
F-actin (Alexa Fluor 555 phalloidin, pink) and nuclei (TO-PRO-3, blue) are shown (n = 4). Scale bar: 100 μm. 
(B) Immunoblot showing ANXA1 in the supernatant and lysate of the ex vivo culture. Densitometry analysis 
shows that ANXA1 protein in culture supernatants derived from wounded cultures is significantly increased 
versus nonwounded cells (1.979-fold increase, P = 0.0024 average of n = 3 immunoblots). In total lysate, the 
ratio of ANXA1 expression in wounded tissue versus nonwounded tissue is 0.762 (P = 0.0005 average of  
n = 3 immunoblots). (C) EVs (microparticles and exosomes) were stained with BODIPY-Texas Red and conju-
gated CD11b, A33, and ANXA1 fluorescent antibodies. Data are expressed as mean ± SEM; n = 4 per group.  
(D) EVs derived from Anxa1+/+ and Anxa1–/– mice were added to monolayers of cultured murine epithelial cells, 
and scratch wound resealing assay was performed. Increased wound closure was observed after incubation 
with ANXA1-containing EVs (**P = 0.0025) compared with EVs lacking ANXA1. Mean ± SEM; n = 15 mice per 
group. Statistical comparisons were performed by ANOVA with Tukey’s multiple comparison post-test.
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(Hydro-Cy3) dye, which fluoresces when oxidized (25). As shown 
in Figure 2, E and F, incubation of resealing wounds with EVs 
increases ROS generation at the wound edge, consistent with the 
effects previously observed with the ANXA1 mimetic peptide (7).
To further verify the above in vitro results, we isolated EVs 
from ex vivo resealing murine intestinal mucosal wounds in wild-
type mice (Anxa1+/+ EVs) and ANXA1-null mice (Anxa1–/– EVs). 
As shown in Supplemental Figure 2B, ANXA1 protein expression 
was absent in Anxa1–/– mice. A total of 3 colonic mucosal biopsy- 
induced wounds per mouse were obtained (7, 26). Resealing colonic 
wounds and their adjoining intact mucosa were later harvested for 
ex vivo culture (Figure 3A). ANXA1 protein in the culture media 
as well as in murine tissue was analyzed by immunoblotting and 
by Amnis ImageStream X Mk II imaging flow cytometry. ANXA1 
release was higher in supernatants from wounded mucosa of wild-
type mice compared with that in nonwounded mucosal tissue 
1 day after injury (Figure 3B). This flow cytometry technique iden-
tified several EV subtypes (exosomes and microparticles; Figure 
3C) in the supernatant of wounded mucosa and elucidated their 
cell of origin. The vast majority of CD11b+ EVs were positive for 
ANXA1. The A33 antigen, a transmembrane protein expressed 
almost exclusively by epithelial cells, was also used to detect 
lial wound repair, resealing IEC wounds were incubated with fluo-
rescently labeled EVs (using CFSE) (Figure 2A). Indeed, visualized 
labeled EVs were associated with epithelial cells and significantly 
enhanced wound repair (P < 0.0001), as shown in Figure 2B. Since 
FPRs mediate ANXA1 signaling to promote IEC wound repair (4, 
7, 23), we examined whether the FPR1 and FPR2/ALX antagonists 
(CsH and WRW4) influenced ANXA1-containing EV–mediated 
IEC wound closure. As shown in Figure 2C, inhibition of both 
receptors abrogated the prohealing effects of ANXA1-containing 
EVs. Furthermore, incubation of resealing wounds with EVs in the 
presence of a neutralizing anti-ANXA1 antibody (24), but not con-
trol IgG, inhibited EV-mediated increase in wound closure (Figure 
2D). Interestingly, another member of the annexin protein family, 
ANXA5, also identified in epithelial-derived EVs, did not promote 
wound closure (Supplemental Figure 1E). These findings support 
a specific role of ANXA1-containing EVs in signaling via FPRs to 
promote IEC wound healing.
We have previously reported that ANXA1 promotes IEC wound 
repair by ROS generation mediated by FPR and NOX1 signaling 
(7). To test whether IEC exposure to ANXA1-containing EVs also 
induces ROS generation, we visualized superoxide production 
using the stable and nontoxic redox-sensitive hydrocyanine 3 
Figure 4. Serum-derived exosomes from healthy 
controls and patients with IBD. (A and B) Immu-
noblots of ANXA1, CD9, and ANXA5 in isolated 
exosomes from sera of human (A) healthy controls 
and (B) patients with IBD. Exosomes were precip-
itated from human pooled sera using SBI’s Serum 
ExoQuick precipitation reagent (data are represen-
tative of n = 3 experiments). (C) Representative 
side scatter versus bright-field area (SSC/Ch12) and 
Ch04 fluorescence plots for EV isolates acquired 
with 1-μm and 500-nm reference beads (100-nm 
and 50-nm beads were acquired separately and 
overlaid) of EVs isolated from human sera by 
ultracentrifugation (n = 3). (D) Representative 
bright-field (Ch01), Ch04, and Ch012 images of 
each population of beads and EVs (n = 3) (original 
magnification, ×60). Scale bar: 7 μm. (E) EVs were 
stained with BODIPY-Texas Red and conjugated 
fluorescent antibodies against ANXA1 (n = 3). 
Data are expressed as mean ± SD. *P = 0.0194. 
Statistical comparisons were performed by 2-tailed 
Student’s t test.
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ANXA1-containing EVs derived from the epithelium (27). Finally, 
the functional influence of EVs derived from ex vivo cultures 
on wound closure was assessed in a murine IEC line (CMT-93). 
Supporting our hypothesis, we observed increased wound repair 
mediated by Anxa1+/+ EVs but not Anxa1–/– EVs (Figure 3D).
Taken together, these data suggest that ANXA1 is released as a 
component of EVs to promote wound repair.
ANXA1 in EVs is increased in the sera from patients with inflam-
matory bowel disease. Intestinal epithelial injury and mucosal 
inflammation are diagnostic pathologic features seen in patients 
with intestinal inflammatory disorders, such as inflammatory 
bowel disease (IBD). Since EVs are emerging as novel effectors 
of intertissue communication (10, 28), we hypothesized that 
increased ANXA1-containing EVs could be identified in the sera 
of patients with active IBD. Thus, we analyzed exosomes isolated 
from sera of individuals with IBD and healthy controls. Indeed, 
as shown in Figure 4, A and B, increased ANXA1 was detected in 
CD9- and ANXA5-containing exosomes isolated from individu-
als with active IBD compared with sera from healthy individuals. 
Supplemental Table 1 provides preoperative endoscopic findings 
and postoperative histologic diagnosis. For two patients with 
clinical diagnosis of acute colitis, no histologic scoring could be 
obtained, since no bowel specimen was resected. Concerning the 
diagnoses, some patients had active Crohn’s disease, whereas 
others had active ulcerative colitis. Histologic examination of all 
surgical specimens revealed active mucosal inflammation. In our 
analysis, patients with high inflammatory activity also showed 
higher yields of ANXA1-containing EVs in their sera, as shown 
in the immunoblots in Figure 4B. However, diagnosis of Crohn’s 
disease versus ulcerative colitis cannot be distinguished based 
on the immunoblotting results. These findings suggest that, 
while ANXA1-containing EVs in the serum correlate with the 
severity of acute mucosal inflammation, they do not distinguish 
the underlying mucosal disease.
Next, EVs in the serum were analyzed by flow cytometry 
using reference beads of known sizes, ranging from 1 μm to 50 nm 
(Figure 4, C–E). This analysis confirmed that increased ANXA1- 
containing EVs in the sera of patients with active IBD (Figure 4E) 
were derived in part from the epithelium (see Supplemental Figure 
1F). Our findings are supportive of those of a previous study that 
reported endogenous ANXA1 secretion in the colons of human 
patients with ulcerative colitis (29).
Therapeutic administration of collagen IV–targeted polymeric 
NPs containing a ANXA1 mimetic peptide promotes recovery from 
dextran sulfate sodium colitis. To exploit the physiological mech-
anism of repair mediated by ANXA1-containing EVs, we inves-
tigated the therapeutic potential of targeted NPs containing the 
ANXA1 mimetic peptide Ac2-26 on mucosal repair in vivo. To 
Figure 5. NPs containing Ac2-26 
accelerate recovery of murine colitis 
in vivo. (A) Clinical disease activity 
index (DAI) of Anxa1–/– mice sub-
jected to DSS colitis (7 days) followed 
by recovery from colitis (6 days). 
NPs and Ac2-26 peptide alone were 
administered only once via intraperi-
toneal injection (4 μg per mouse) at 
the first day of recovery (*P < 0.001). 
(B) Representative photomicrographs 
of hematoxylin and eosin–stained 
histological sections (original 
magnification, ×2). (C) Analysis of 
percentage of ulceration in whole 
colon samples (*P = 0.0131 vs. Scrm 
Ac2-26 Col IV NPs). (D) Fecal lipocalin 
analysis (*P = 0.0037 vs. Scrm Ac2-26 
Col IV NPs; n = 10 mice per group). 
Quantitative data are expressed 
as mean ± SEM for each treatment 
group. Statistical comparisons were 
performed by ANOVA with Tukey’s 
multiple comparison post-test.
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analyze mucosal repair from acute epithelial injury associated 
with mucosal inflammation, we used the murine dextran sulfate 
sodium (DSS) model of colitis (30). DSS was administered for 
7 days and then withdrawn to allow recovery from colitis. The dis-
ease activity index was monitored over this entire period.
The NPs used in these experiments have previously been 
shown to have antiinflammatory properties (15). NPs were engi-
neered to have a surface decorated with collagen IV, since it rep-
resents one of the main components of the basement membrane 
and therefore can enable targeting of NPs to vessels and injured 
Figure 6. Intramucosal injections 
of Ac2-26 Col IV NPs augment 
colonic mucosal wound heal-
ing. (A) Images obtained during 
colonoscopy showing intramucosal 
injection of NPs in the mucosal 
wound bed. The arrow delineates 
the area of submucosal injection. 
(B) Schematic showing intramu-
cosal NP injection into the colonic 
mucosal wounds. (C) Frozen sec-
tions of resealing colonic wounds 
in Anxa1+/+ mice showing ANXA1 
(red), F-actin (Alexa Fluor 488 
phalloidin, green), and NPs (Alexa 
Fluor 647, blue). Higher-magnifica-
tion images (original magnification, 
×40) of the boxed region (original 
magnification, ×20) are shown to 
the right. Scale bar: 50 μm. (D) 
Frozen sections labeled for F-actin 
(Alexa Fluor 555 phalloidin, red). 
Released Ac2-26-FAM is shown in 
green and labeled Ac2-26 Col IV NPs 
are shown in blue. A higher-magni-
fication image of the boxed region 
is shown to the right. Scale bar: 50 
μm. (E) Immunoblot analysis of 
ANXA1 expression in nonwounded 
and resealing wounds of Anxa1+/+ 
mice. Equivalent amounts of 
protein were loaded. From densit-
ometry analysis ANXA1 protein in 
wounded tissue is increased versus 
nonwounded cells (2.568-fold 
increase, P = 0.0005, average of  
n = 3 immunoblots). (F) Endoscopic 
images of healing colonic mucosal 
wounds 1 or 3 days after biop-
sy-induced injury in Anxa1–/– mice 
treated with NPs. (G) Quantifi-
cation of wound repair. Data are 
expressed as mean ± SEM; n = 15 
mice per group. ***P < 0.0001 vs. 
Scrm Ac2-26 Col IV NPs and vs. Ac2-
26. Statistical comparisons were 
performed by ANOVA with Tukey’s 
multiple comparison post-test. 
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Intramucosal administration of Ac2-26 NPs accelerates intestinal 
mucosal wound healing. A major advantage of using NPs is that they 
can provide a platform for sustained and direct release of the prore-
solving peptide (Ac2-26) at the site of administration. To further 
demonstrate this beneficial effect, we investigated the influence of 
NPs on healing of intestinal mucosal biopsy-induced wounds in WT 
mice generated using a mouse colonoscope (7, 26). A single intra-
mucosal injection of NPs or Ac2-26 peptide alone into the wound 
bed was performed (Figure 6, A and B, and Supplemental Video 1), 
and wound healing was analyzed 3 days later. As shown in Figure 6, 
C and D, fluorescent NPs and labeled peptide Ac2-26 released from 
NPs could be identified in the wound bed 3 days after administra-
tion. Since endogenous ANXA1 protein was increased in resealing 
mucosal wounds 3 days after injury (Figure 6E), we next examined 
the influence of intramucosal delivery of Ac2-26 Col IV NPs into 
intestinal mucosal wounds in ANXA1-deficient mice. In keeping 
with improved recovery from DSS colitis, intramucosal adminis-
tration of Ac2-26 Col IV NPs increased wound repair compared 
with administration of Scrm Ac2-26 Col IV NPs or a single injection 
of Ac2-26 peptide (Ac2-26 Col IV NPs: 62.96% ± 3.08% vs. Scrm 
Ac2-26 Col IV NPs: 29.15% ± 3.6%, P < 0.0001; Figure 6, F and G).
mucosa (31). NPs containing a scrambled peptide (Scrm Ac2-26 
Col IV NPs) and free Ac2-26 peptide were used as controls. To 
control for specificity of the exogenous Ac2-26–mediated effects, 
all in vivo experiments were performed in Anxa1–/– mice. In vitro, 
the NPs containing Ac2-26 (Ac2-26 Col IV NPs) showed increased 
IEC adherence and wound closure compared with those NPs con-
taining Scrm Ac2-26 Col IV NPs, as shown in Supplemental Fig-
ure 2C. In vivo, Ac2-26 Col IV NPs, Scrm Ac2-26 Col IV NPs, and 
Ac2-26 alone were administered by intraperitoneal injection on 
the first day of recovery (Figure 5A). A single injection of Ac2-26 
Col IV NPs promoted repair of the intestinal mucosa, as judged by 
the disease activity index, compared with Scrm Ac2-26 Col IV NPs 
or Ac2-26 alone (Figure 5, A–C).
Histological analysis confirmed decreased intestinal mucosal 
ulceration in mice treated with Ac2-26 Col IV NPs. Similarly, fecal 
lipocalin-2, used as an inflammatory marker, was also reduced in 
mice administered Ac2-26 Col IV NPs compared with that in those 
administered Scrm Ac2-26 Col IV NPs or Ac2-26 alone (Figure 5D 
and ref. 32). Altogether, these results suggest that a single admin-
istration of Ac2-26 Col IV NPs mediates a potent and sustained 
effect on recovery from acute colitis.
Figure 7. Endogenous epithelial-derived ANXA1-
containing EVs and exogenous administration 
of Ac2-26 Col IV NPs activate FPRs to promote 
wound repair. Epithelial cells adjoining the wound 
flatten out, change polarity, and migrate as a 
sheet to cover denuded surfaces. Immune cells 
infiltrate into the site of injury in mucosal wounds. 
The healing epithelium is exposed to infiltrating 
immune cells that coordinate the mucosal repair. 
During this process, epithelial cells and immune 
cells release EVs (microparticles and exosomes) 
containing proresolution mediators, including 
ANXA1. ANXA1 in EVs signals through epithelial 
FPRs (FPR1 and FPR2/ALX) to promote wound 
repair (acting as an endogenous mediator of wound 
repair). This prorepair effect of endogenous ANXA1 
can be mimicked using synthetically derived NPs 
containing ANXA1 mimetic peptide Ac2-26. Intra-
mucosal injection of Ac2-26 Col IV NPs enhances 
epithelial wound healing (after exogenous admin-
istration of ANXA1).
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more, ANXA1 in epithelial-derived EVs is in large part distributed 
on the surface of cells (Supplemental Figure 2A).
FPR1 and FPR2/ALX, receptors for ANXA1 and ANXA1 
mimetic peptide Ac2-26, are localized in both the luminal apical 
plasma membrane as well as in the basolateral membrane of IECs. 
After tissue injury the polarity of epithelial cells that migrate as a 
sheet to cover denuded mucosal surfaces is changed. Epithelial 
cells at the leading edge flatten out, and a clear distinction between 
apical and basolateral plasma membrane is not evident. ANXA1 
that is exteriorized and released in EVs binds and activates FPRs 
in the plasma membrane of the migrating sheet of epithelial cells.
Importantly, recent studies have highlighted a role of EVs 
released from cells in mediating cross talk between different cell 
types (10, 28). Macrophages reside in close proximity to the repair-
ing epithelium and have been shown to attenuate the immune 
response while also promoting the extracellular matrix remodel-
ing required for wound repair (49). Furthermore, macrophages 
generate maresins that exert proresolving effects in inflammation 
(50, 51). In addition to macrophages, neutrophils in wounds shed 
microparticles containing ANXA1 that activate FPRs in leukocytes 
(8) as well as in the epithelium to promote resolution of inflam-
mation and repair. A recent study reported a novel approach using 
human polymorphonuclear cell–derived microparticles enriched 
in resolvin D1 and lipoxin A4 analogs in facilitating resolution of 
inflammation in murine peritonitis (52).
IBD is pathologically characterized by mucosal inflammation 
and, during active phases of the disease, by infiltration of neu-
trophils and mucosal ulceration (53, 54). To determine whether 
ANXA1-containing EVs could serve as a biomarker of active IBD, 
we analyzed EVs in the sera of healthy controls and patients with 
IBD. Disease severity was assessed clinically and endoscopically 
and by histologic analysis of resected surgical specimens where 
applicable (see Supplemental Table 1). All patients presented clin-
ical signs of acute disease of different levels of severity. Patients 
with increased active mucosal inflammation exhibited elevated 
ANXA1-containing EVs in the sera compared with patients with 
milder disease activity. However, we detected ANXA1-contain-
ing EVs in all patients with active mucosal inflammation. Since a 
previous study has reported expression of ANXA1 by neutrophil- 
derived EVs (8), we predict that in the local microenvironment 
of the wound, ANXA1-containing EVs might be derived not only 
from infiltrating leukocytes but also from the repairing epithe-
lium. In fact, we demonstrated the presence of ANXA1-containing 
EVs that colabeled with an epithelial-derived protein, A33, in ex 
vivo cultures of wounds (55). In conclusion, detection of ANXA1-
containing EVs in the serum could serve as a biomarker for active 
mucosal inflammation (56).
NPs can be used as a pharmacological approach that can 
improve bioavailability and tissue distribution and half-life of the 
administered agent and minimize systemic undesired effects and 
therefore have therapeutic potential for use in wound repair asso-
ciated with inflammation as well as in tissue regeneration. In our 
study, the therapeutic effects of Ac2-26 Col IV NPs were tested in 
two injury and inflammation models that include recovery from 
DSS colitis and resealing of colonic biopsy-induced wounds. These 
models are amenable to detailed morphological analysis of resolu-
tion of mucosal inflammation and repair of the intestinal epithe-
Discussion
Timely and efficient intestinal mucosal wound repair, coinciding 
with resolution of inflammation, is critical in reestablishing the 
epithelial barrier and mucosal homeostasis. We and others have 
shown that ANXA1 and its N-terminal peptide, Ac2-26, have epi-
thelial prorepair properties that require the activation of FPRs (4, 
5, 7). Resolution of inflammation and repair of the epithelial bar-
rier are mediated by a delicate choreography of mediators derived 
from the epithelium as well as by inflammatory cells in the lamina 
propria of the mucosa. Thus, an improved understanding of these 
biological processes is important in development of therapeu-
tic strategies designed to promote recovery of epithelial injury in 
inflammatory states such as IBD (1, 33).
Recent studies have identified a number of mediators that play 
an active role in the resolution of inflammation, including ANXA1, 
lipoxins, resolvins, protectins, and maresins (3, 34–37). ANXA1 is 
expressed by a number of cell types, including epithelial cells and 
phagocytes, and mediates its biological responses by activating 
FPRs that are expressed in both phagocytes and epithelial cells. 
Three FPRs (FPR1, FPR2/ALX, and FPR3) have been identified in 
humans (38). The ANXA1 N-terminal peptide, Ac2-26, preferen-
tially associates with epithelial FPR1 to promote intestinal wound 
repair (7, 23). In this study, we report that ANXA1 is released from 
IECs as a component of EVs and that these EVs possess prorepair 
properties. Remarkably, EVs derived from Anxa1–/– mice failed to 
enhance epithelial wound healing. A schematic representation of 
our results is shown in Figure 7. Endogenous ANXA1 released in 
EVs from epithelial cells and leukocytes after injury orchestrates 
epithelial wound repair. Furthermore, in vivo, local administration 
of synthetic NPs containing Ac2-26 mimics the prorepair effects of 
epithelial and immune cell–derived EVs. Additionally, a previous 
study reported ANXA1 association with the exoplasmic surface 
of vesicles secreted by prostate epithelial cells into the seminal 
fluid or prostasomes may contribute to suppression of the immune 
response in the female reproductive tract (39).
The extracellular influence of ANXA1 is regulated by proteo-
lytic cleavage of the N terminus of the protein by MMPs. Increased 
MMP activity has been identified in inflamed tissues and such 
MMP activity has been reported to dampen inflammation by pro-
moting cleavage of chemokines (16, 40). Given this scenario, one 
can envision that increased MMPs facilitate resolution of inflam-
mation both by promoting cleavage of ANXA1 and release of the 
N-terminal peptide, Ac2-26 (7, 41–46). Pharmacological inhibition 
of MMP9 markedly reduced ANXA1 detection in EVs (Supple-
mental Figure 1, A and B). MMP9 activation during inflammation 
is therefore likely to play an important role in ANXA1 proteolysis. 
Upon cellular activation, ANXA1 is released from its storage sites 
and translocates immediately to the membrane. In neutrophils, 
ANXA1 is stored in gelatinase granules, and upon neutrophil- 
activating events, such as adhesion to the endothelium, it is rapidly 
exteriorized (47), exposing the N-terminal region that mediates 
its biological response (Figure 3D). Neutrophil ANXA1 external-
ization can occur without interaction with endothelial cells, indi-
cating that cellular adhesion to the endothelium is not required 
for release of ANXA1 (48). For the first time to our knowledge, 
we show that epithelial-derived ANXA1-containing EV release is 
highly regulated by wounding (as shown in Figure 3B). Further-
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labeled phalloidin (catalog no. R415), Exosome-Dynabeads Human 
CD63 Isolation/Detection (catalog no. 10606D), ExoQuick serum 
exosome precipitation solution (catalog no. EXOQ5A-1), and BCECF, 
AM (catalog no. B-1150) were purchased from Life Technologies 
(Invitrogen). EpCAM magnetic beads (catalog no. 130-061-10) were 
purchased from Miltenyi Biotec. Hydro-Cy3 Dye (product no. 926-
20000; product name: ROSstar 550 Probe) was purchased from LI-
COR. Compound GI254023X (catalog no. 3995) was purchased from 
Tocris; TAPI-2 (catalog no. 579052) and MMP9 II inhibitor (catalog 
no. 444293) were purchased from EMD Millipore; and Cyclosporin H 
(catalog no. ALX-380-286-M001) was purchased from EnzoLife 
Bioscience. BAPTA-AM (catalog no. 2787), ML-7 (catalog no. 4310), 
Y-27632 (catalog no. 1254), Dynasore (catalog no. 2897), Cytocha-
lasin D (catalog no. 1233), Jasplakinolide (catalog no. 2792), WRW4 
(catalog no. 2262), and ANXA5 (catalog no. 10448-HNAE) were pur-
chased from Invitrogen. Z-VAD-FMK (catalog no. 187389-52-2) was 
purchased from Santa Cruz Biotechnology. Cytokines (IL-1β, IFN-γ, 
and TNF-α) were obtained by Peprotech. Human recombinant ANXA1 
(hrANXA1) was purified as previously reported (7).
Mice. Wild-type mice were purchased from The Jackson Labora-
tory. Anxa1–/– mice were generated as previously described (63).
Cell lines and culture conditions. IECs (SK-CO15 [human] and 
CMT-93 [murine]) were obtained from the Digestive Diseases 
Research Development Center Cell Culture Core (Emory University, 
Atlanta, Georgia, USA). SK-CO15 cells were grown in high glucose 
(4.5 g/l), DMEM supplemented with 10% FBS, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, 15 mm HEPES (pH 7.4), 2 mm l-gluta-
mine, and 1% nonessential amino acids, as described previously (59), 
at 37°C in a 4% CO2 incubator.
Polymeric Ac2-26 Col IV NPs. Targeted polymeric Ac2-26 Col IV NPs 
and Scrm Ac2-26 Col IV NPs were made and characterized according to 
previously published protocols (15). NPs were labeled with Alexa Fluor 
647 and fluorescent Ac2-26-FAM for detection at the site of injection.
DSS colitis. Mice were allowed free access to food and drinking 
water containing 3% (w/v) DSS for 7 days, and recovery was allowed 
for additional 6 days. Daily clinical assessment and histological analy-
sis were performed as previously described (60, 61).
Confocal immunofluorescence microscopy. Tissue was fixed with 
3.7% (w/v) paraformaldehyde at room temperature for 15 minutes, 
followed by 0.5 % (w/v) Triton X-100 for 5 minutes. Primary antibody 
incubation was performed overnight. Images were taken on an LSM 
510 confocal microscope (Zeiss).
Wound healing assay. Cell migration was assessed using a scratch 
wound assay as previously published (59). Inhibitors were added 30 
minutes prior to the mechanical wound injury. In some experiments, 
epithelial cells were incubated with EVs (2 μg) or hrANXA1 (10 nM). 
For immunoblot analysis, confluent cell monolayers grown in 6-well 
tissue culture plates were scraped 8 times horizontally and vertically 
to enrich for migrating cells.
Cell surface biotinylation. IECs were plated in a 6-well plate and incu-
bated on ice in PBS containing 500 μg/ml sulfo-NHS-biotin. After aspira-
tion, cells were washed twice with 10 mM Tris-HCl, pH 7.2, and 150 mM 
NaCl to quench the biotinylation reaction. Scratch wound assay was per-
formed. After 4 hours, wound healing the supernatant was incubated with 
avidin-coated agarose beads overnight. Immunoprecipitates of biotiny-
lated surface proteins bound to avidin-agarose were washed 5 times in 
RIPA buffer and analyzed for ANXA1 using the immunoblot technique.
lium. In addition to systemic administration, local intramucosal 
delivery of Ac2-26 Col IV NPs, recently tested in vivo in zymosan- 
induced peritonitis and murine models of ischemia-reperfusion 
injury, was sufficient in promoting colonic mucosal wound repair 
(15). NPs used as peptide carriers are highly stable and therefore 
require reduced peptide dosing, demonstrating that this mode of 
administration is a technological advance. In addition, the choice 
of encapsulation of Ac2-26 versus the whole protein was based on 
the fact that ANXA1 is highly susceptible to proteolytic cleavage 
within the N terminus by MMPs in the injured mucosa. Further-
more, NPs injected via the intramucosal route, as presented in our 
study, restricted access of the Ac2-26 peptide to specific sites of 
wounded colonic mucosa, thereby delivering the prorepair pep-
tide at a controlled and sustained rate (over 4 days). Furthermore, 
the NPs were not eliminated from the intestine by diarrhea that is 
associated with mucosal inflammation and injury (57, 58). Thus, 
this mode of therapy represents an advance in the current experi-
mental approaches used in nanomedicine (57, 58). While our study 
focused on the intestinal tract, NP-mediated delivery of therapeu-
tic peptides is likely a viable strategy that can be used in promoting 
repair of other epithelial surfaces, such as the skin and lung. Given 
the easy access to skin wounds, local delivery to injured sites is a 
feasible option. Additionally, the delivery of NPs into injured respi-
ratory mucosa by aerosolization would be a potential approach 
that could to be explored in future studies. The development and 
engineering of NPs containing proresolving compounds may thus 
establish a new modality of intercellular communication aimed to 
resolve inflammation and repair epithelial barriers.
Methods
Study design. The first objective of this study was to investigate the 
mechanisms by which ANXA1 is released from the cell surface in EVs 
to activate FPRs and promote intestinal epithelial wound repair. As 
the second objective, therapeutic effects of Ac2-26 Col IV NPs were 
investigated both following endoscopic biopsy of colonic mucosa and 
during recovery from DSS colitis. Ac2-26 Col IV NPs were injected 
into the colonic mucosa of biopsy-generated wounds in Anxa1–/– mice. 
Intraperitoneal injections were performed in Anxa1–/– mice with coli-
tis. Parameters for epithelial wound repair were analyzed after 3 days 
of healing in the colonoscopy model (percentage of wound closure) 
and following 6 days of recovery in the colitis model (disease activ-
ity index). Study design and sample sizes were predetermined on the 
basis of previous experience (7), using at minimum 5 mice per group, 
and all experiments were replicated at least 3 times to confirm findings. 
Mice were randomly assigned to treatment groups, and where possible, 
treatment groups were blinded until statistical analysis. No potential 
outliers were excluded from the data sets presented in this study.
Antibodies and reagents. Antibodies to CD9 (catalog no. ab92726), 
CD63 (catalog no. ab134045), ANXA5 (catalog no. ab14196), CD151 
(catalog no. ab185684), and ADAM-10 (catalog no. ab1997) were 
purchased from abcam; MMP2 (catalog no. 4022) and MMP9 (cat-
alog no. 3852) from Cell Signaling; and monoclonal anti–α-tubu-
lin antibody produced in mouse (catalog no. T9026) from Sigma- 
Aldrich. Flotillin-1 antibody (catalog no. 610821) and ANXA1 inhib-
itory antibody (clone 29, catalog no. 610066) were purchased from 
BD Transduction Laboratories. Mouse IgG1 control antibody (catalog 
no. 02-6100), anti-ANXA1 antibody (catalog no. 71-3400), TRITC- 
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Grids with adhered EVs were briefly washed by touching the side of 
grid with EVs to a drop of double-distilled water. For negative stain-
ing, 5 μl 1% aqueous phosphotungstic acid (pH 6.5) was applied onto 
the vesicles on the grid immediately after water removal and then 
removed as described above after 30 seconds. The grid was allowed 
to dry completely before viewing on a JEOL JEM-1400 transmission 
electron microscope (JEOL Ltd.) equipped with a Gatan US1000, 2k × 
2k CCD camera (Gatan Inc.). Immunogold labeling was performed at 
room temperature by floating the grids on drops containing the diluted 
anti-ANXA1, CD9, and ANXA5 primary antibodies. After several buf-
fer washes, the grids were floated on drops of 10 nm colloidal gold par-
ticle–conjugated secondary antibodies for 1 hour.
Ex vivo culture of murine mucosal colonic wounds. Mouse colonic 
small tissue biopsies (4 mm) containing the wounds (obtained by 
colonoscopy technique) were removed with a punch biopsy instru-
ment. Tissues were rinsed with sterile PBS to remove cellular debris 
and immediately placed into a 24-well culture plate (3 wounds from 
each mouse per well). Cultures were maintained for 4 hours at 37°C, 
5% CO2, supernatants were collected, and EVs were isolated.
Statistics. Statistical comparisons were performed by either Student’s 
2-tailed t test or ANOVA with Tukey multiple comparison post-test, as 
appropriate. A P value of less than 0.05 was considered significant.
Study approval. Informed consent was obtained from all patients 
and healthy controls, and research on the obtained samples was per-
formed in accordance with institutional review board approval from 
the University of Muenster (approval no. “1IXHai”). All animal exper-
iments were approved by the Institutional Animal Care and Use Com-
mittee at Emory University and performed according to NIH guidelines. 
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EVs purification and analysis. EVs were isolated and purified using 
a previously published protocol (62). Culture medium was subjected 
to differential centrifugation to remove cells, dead cells, and cell 
debris at a rate of 20,000 g for 20 minutes (microparticles isolation) 
to 100,000 g (for exosome isolation) for 60 minutes. The amount of 
proteins recovered was measured by Bradford assay. For immuno-
blot analysis, EVs were washed once with HBSS and resuspended in 
RIPA lysis buffer. EVs were prepared for ImageStreamX Imaging Flow 
Cytometry analysis as previously described (22). EVs were stained with 
25 μM BODIPY-Texas Red dye, 0.5 μg/ml anti-ANXA1 mAb (clone 1B; 
Alexa Fluor 488 conjugated; produced in-house using a APEX Alexa 
Fluor 488 Antibody Labeling Kit [catalog no. A10468] from Invit-
rogen), anti-CD11b PE (eBioscience), and anti-A33 (R&D Systems) 
antibodies. All staining was carried out at 4°C in the dark for 30 min-
utes. Immediately prior to acquiring each sample, 1-μm and 500-nm 
fluorescent reference beads (catalog no. L1278-1ML and L1403-1ML, 
respectively; Sigma-Aldrich) were added to a final concentration of 1 
in 6 from stock. All samples were acquired on the ImageStreamx MkII 
(Amnis Corp.) at low flow rate, ×60 magnification, and all lasers (488 
nm, 405 nm, 633 nm, and 785 nm) at full voltage. Two separate sam-
ples containing 1× 100-nm beads and 1× 50-nm beads (catalog no. 
L1528-1ML and L0780-1ML, respectively; Sigma-Aldrich) were run to 
generate overlays with EV populations. Isotype control samples for in 
vivo and in vitro data as well as single-color stains for compensation 
were acquired as appropriate. ImageStream data were acquired using 
INSPIRE and analyzed using IDEAS. Sera from patients with IBD and 
healthy individuals were incubated overnight with EpCAM magnetic 
beads (Miltenyi Biotec), followed by immunoblotting.
Detection of ANXA1-containing EVs in sera of patients with active 
IBD. For detection of EVs containing ANXA1, sera of patients with 
active ulcerative colitis or Crohn’s disease was obtained during hospi-
talization of the patients. Except for one patient that did not undergo 
surgery, all samples were taken preoperatively. Details regarding dis-
ease severity, preoperative endoscopic findings and postoperative 
histologic diagnosis are shown in Supplemental Table 1. No histologic 
analysis was obtained for 2 patients, because one patient was treated 
medically and, in the other case, no bowel specimen was removed, but 
both were diagnosed clinically. Healthy non-IBD individuals with no 
other known diseases were used as controls. For isolation of EVs from 
the serum SBI’s Serum ExoQuick precipitation reagent was used.
Detection of intracellular ROS. This was performed as previ-
ously described (7).
Colonoscopy in live mice. Mice were anesthetized by intraperito-
neal injection of a ketamine (10 g/l)/xylazine (8 g/l) solution (10 μl/g 
body weight). To create mucosal injuries in the mouse colon and to 
monitor their regeneration, a high-resolution colonoscopy system was 
used. Each wound region was digitally photographed at day 1 and day 
3, and wound areas were calculated using ImageJ software. In each 
experiment, 3 to 4 lesions per mouse were examined (7).
Quantification of fecal Lcn-2 by ELISA. Lcn-2 levels were estimated 
in the supernatants of freshly collected fecal samples reconstituted in 
PBS containing 0.1% Tween 20 (100 mg/ml) using the Duoset Murine 
Lcn-2 ELISA Kit (R&D Systems).
Electron microscopy. EVs were suspended in PBS and fixed by add-
ing an equal volume of 2% paraformaldehyde in 0.1 M phosphate buf-
fer (pH 7.4). EVs were absorbed for 10 minutes by 400-mesh carbon-
coated copper grids by floating the grids on 10 μl drops on parafilm. 
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